In vitro fertilization and Anti-Mullerian hormone

Yıl 2008, Cilt 39, Sayı 1, 27 - 31, 01.02.2008

Namık Kemal DURU Seyit Temel CEYHAN İbrahim ALANBAY Murat MUHCU Uğur KESKİN İskender BAŞER

Öz

Anti-Mullerian hormone (AMH), is a glycoprotein structured molecule. AMH plays an important role in male sex differantiation and female folliculogenesis. It has an inhibitor role infolliculer selection period. It's serum consantrations increase in puberty, decrease in menapose andrnaximun in reproductive period in female. This review describes several studies showing that AMH serum level is avaiable to evaluate ovarian response, ovarian reserve, luteal phase and IVF outcome in IVF practise, and the diagnosis and management of polycistic over disease (PCOD) and primer ovarian failure (POF) due to cancer terapy, and non- obstructive asospermi and operative ovarian injury.

Anahtar Kelimeler

Anti-Mullerian Hormone, Fertilization in Vitro, Polycystic Ovary Syndrome, Azoospermia

Anti Müllerian Hormon düzeylerinin invitro fertilizasyonda kullanımı

Öz

Anti Müllerian Hormon (AMH) glikoprotein yapıda bir molekül olup temel olarak erkek seks diferensiasyonunda regulatuar rol oynamaktadır. Erkekte fetal testisin sertoli hücreleri tarafından salgılanmakta iken, dişilerde gelişmekte olan follikülün granüloza hücreleri tarafından s algılanmaktadır. Erkekte Müllerian kanal regresyonunda rol almakta olup, kadınlarda follikül seçiminin inhibisyonunda rol oynamaktadır. Antimüllerian hormon, erkekte, prenatal ve yeni doğan döneminde yüksek konsantrasyonlarda salınmakta olup, puberte döneminde düzeyi daha düşük seyretmektedir. Kadınlarda ise, puberte döneminde artış göstermeye başlayıp, reprodüktif dönemde en üst düzeye çıkmaktadır. Menopoz döneminde ise azalmaktadır. Follikülogeneziste, primordial follikül evresinden preantral follikül evresine geçiş olan inisiyel seçim aşamasında AMH inhibitor rol oynamaktadır. AMH seviyeleri IVF te; ovarian yanıt belirteci, ovarian rezerv belirteci, Lutealfaz belirteci, IVF outcome belirteci, PCOS tanı / tedaviye yanıt, POF- Kanser tedavisi sonrası ovarian hasar, Non-obstruktifAzospermi ve operatif ovarian hasarın değerlendirilmesinde kullanılabilmektedir.

Anahtar Kelimeler

Anti-Mullerian Hormon, İnvitro fertilizasyon, Polikistik yumurtalık sendromu, Azoospermi

Kaynakça

• 1. Baarends WM, UiJenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA . Anti-müllerian hormone and anti-müllerian hormone type II receptor messengerribonucleicracid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. 1995,136(11), 4951-4562
• 2. Weenen C, Laven JS, Von Bergh AR, Cranfleld M, Groome NP, Vis ser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment 2004, 10(2), 77-83
• 3. Themmen AP. Anti-Mu'llerian hormone: its role infollicular growth initiation and survival and as an ovarian reserve marker 2005, 34, 18-21
• 4. Rey et al, Human Pathology, 2000, 31, 1202- 1208
• 5. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, Volpe A. Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 2004, 19 (12), 2738-2741
• 6. La Marca et al, Hum Reprod, 2006, 21, 2022- 2026
• 7. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod, 2002, 17(12), 3065-3071
• 8. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, Carmona F, Vanrell JA, Balasch J. Basal and stimulation day 5 anti- Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist— gonadotropin treatment. Hum Reprod, 2005, 20(4), 915-922
• 9. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, BouyerJ. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod, 2005, 20(4), 923-927
• 10. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ Dynamic assays ofinhibin B, anti-Mullerian hormone and estradiol followin g FSH stimulatio n and ovarian ultrasonography as predictors oflVF outcome
• Hum Reprod, 2005, 20(11), 3178-3183
• 11. La Marca et al, Hum Reprod Adv Ace, 2006 21,3103-3107. 12. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS
• Serum anti-MAVMerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with poly cystic ovary syndrome. Hum Reprod, 2005, 20(7), 1820-1826
• 13. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism.Hum Reprod, 2005, 20(7), 814-819
• 14. Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod, 2007, 22(1), 117-123
• 15. Fanichel P, Rey R, Poggioli S, Donzeau M, Chevallier D, Pointis G. Anti-Mullerian hormone as a seminal marker for spermatogenesis in non- obstructive azoospermia. Hum Reprod, 1999, 14(8), 2020-2024
• 16. Fujisawa M, Yamasaki T , Okada H , Kamodino S. The significance of anti-Mullerian hormone concentration in seminal plasma for spermatogenesis 2002, 17(4), 968-970